Verastem, Inc. (VSTM)
Verastem, Inc. (VSTM) is a biotechnology company focused on developing and commercializing medicines for cancer treatment. The company emphasizes targeting cancer stem cells to improve therapy outcomes, with a portfolio that includes drugs aimed at Kuren and other oncology indications. Founded in 2010, Verastem aims to advance innovative approaches to solid tumor and hematologic cancers.
Company News
Despite regulatory challenges and budget cuts, the oncology market is projected to reach US$900 billion by 2034, with several biotech companies advancing innovative cancer therapies and demonstrating promising clinical trial results.
The Portnoy Law Firm has initiated an investigation into Verastem, Inc. (NASDAQ: VSTM) for potential securities fraud after the company disclosed serious adverse events in a clinical trial, causing a significant drop in its stock price.
Verastem Oncology is on track to secure a drug approval for avutometinib, but their low cash position poses a significant risk. Find out why VSTM stock is a Buy.
Verastem (VSTM) gains 57% post-market on achieving a confirmed partial response in 83% of first-line patients treated with novel combo therapy in the initial cohort of its phase I/II pancreatic cancer study.
Avoid these mistakes when you're trading penny stocks The post Trading Penny Stocks This Week? 3 Mistakes to Avoid appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.